MPH Health Care AG

  • WKN: A0L1H3
  • ISIN: DE000A0L1H32
  • Land: Deutschland

Nachricht vom 30.08.2016 | 09:38

MPH Mittelständische Pharma Holding AG: Preliminary IFRS results for first half-year 2016:

DGAP-News: MPH Mittelständische Pharma Holding AG / Key word(s): Half Year Results/Dividend

2016-08-30 / 09:38
The issuer is solely responsible for the content of this announcement.


MPH Mittelständische Pharma Holding AG:

Preliminary IFRS results for first half-year 2016:

Net profit EUR 19.88 million (46 Cent per share) in first half-year, profit increase in second quarter of 29% compared to first quarter 2016, equity EUR 153.49 million (3.58 EUR per share)

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), reports its preliminary IFRS Group results for the first half-year 2016.

In the first half-year 2016 the preliminary IFRS Group net profit amounted to EUR 19.88 million.

The investments listed on Frankfurt Stock Exchange, HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG performed successfully in the first half-year 2016.

HAEMATO achieved in the first half-year sales growth and profit (EBIT) growth of 40%. M1 Kliniken AG enlarged the clinic in Berlin to six operating rooms and 34 patient beds. After further openings M1 is now active with twelve M1-outpatient service centres throughout Germany.
Sales of EUR 18.5 million in the first half-year shall be outperformed in the second half-year. Both companies, HAEMATO and M1, paid a dividend of 30 Cent per share to their shareholders in June 2016.

CR Capital Real Estate AG reported on its general annual meeting on August 18th about progress in the project developments.

MPH paid a dividend of 12 Cent per share in June 2016.

"The net income of EUR 11.19 million in the first quarter outperformed the net income of EUR 8.69 million achieved in the first quarter by 28.7%

We saw in the second quarter a successful development in the effort to make a contribution in keeping healthcare affordable and we are confident for the further income development in 2016", say Patrick Brenske und Dr. Christian Pahl, Members of the Management Board of MPH.

About MPH Mittelständische Pharma Holding AG:

MPH AG is an investment entity strategically focused on the purchase, development and sale of companies and shares in companies especially from the growth segments of the healthcare market. This includes insurance reimbursed segments as well as privately financed segments. But also beyond the healthcare market MPH makes use of potentials of high growth areas.

Key figures for the share of MPH Mittelständische Pharma Holding AG:
Subscribed capital: EUR 42,813,842
Listed shares: ordinary shares
ISIN: DE000A0L1H32
WKN: A0L1H3
Stock symbol: 93M

Contact:
Susanne Seger
MPH Mittelständische Pharma Holding AG
Grünauer Straße 5
D-12557 Berlin

Phone: +49 (0) 30 897308660 Fax: +49 (0) 30 897308669
E-Mail: ir@mph-ag.de Web: www.mph-ag.de



2016-08-30 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


show this

GBC im Fokus

Aves One AG: kursziel deutlich angehoben

Die Aves One AG ist im Geschäftsjahr 2017 abermals dynamisch gewachsen. Der Umsatz stieg um fast 90 % auf über 53 Mio. EUR an. Der jetzt gemeldete Erwerb von umfangreichen Rail-Assets (VTG/Nacco-Deal) soll zu weiteren Steigerungen beitragen. Wir erwarten weiteres Wachstum von über 40% im laufenden Jahr sowie einen dynamischen Anstieg in den Folgejahren. Das Ziel von 1 Mrd. Assets und Managment könnte bereits 2019 und damit ein Jahr früher erreicht werden. Unsere Analysten sind vom VTG/Nacco-Deal überzeugt und haben das Kursziel deutlich auf 12,10 Euro erhöht (bisher 9,10 Euro).

Aktueller Webcast

EQS Group AG

Half-yearly financial statements 2018

16. August 2018

Aktuelle Research-Studie

Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index

20. August 2018